RekrutujeFaza IV
Niewydolność serca: badanie kliniczne fazy IV
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
W Polsce: RekrutujeNa świecie: Rekrutuje
Zawał serca: badanie kliniczne
Tytuł w rejestrze: Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression
Najważniejsze informacje
- Choroba
- Zawał serca (Coronary Artery Disease, Coronary Atherosclerosis, Nicotine Dependence)
- Status w Polsce
- Rekrutujestany polskich ośrodków według ClinicalTrials.gov
- Status na świecie
- Rekrutujestan całego badania w rejestrze
- Wiek uczestników
- 18-75 lat
- Płeć
- kobiety i mężczyźni
- Planowana liczba uczestników
- łącznie 180
- Terminy (planowane)
- 9 lutego 2023 - 31 grudnia 2025
- Kraje
- 1: Polska
- Numer w rejestrze
- NCT05660798 (ClinicalTrials.gov)
Gdzie prowadzone jest badanie
Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:
- WarszawaKontakt
rekrutuje wkrótce nie rekrutuje lub brak danych
Kliknij kropkę, żeby zobaczyć ośrodki w mieście.
Więcej badań w tych miastach:
Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
Objective:
To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.
Rationale:
Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.
The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.
Leczenie w badaniu
| Lek / interwencja | Rola | Postać, podanie |
|---|---|---|
| heated tobacco - lifestyle intervention | Interwencja behawioralna |
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (7)
- Adults aged >18 years and <75 years
- Subjects with stable chronic coronary syndrome defined as the presence of at least one coronary artery stenosis >=20% due to coronary plaque visible on coronary computed tomography angiography (CCTA), in an artery with a reference diameter > 2.0mm
- History of smoking pack-years ≥10 (Pack-years will be calculated by taking the average number of cigarettes smoked per day divided by 20 and multiplied by the number of years smoked), based on self-reporting
- Current smokers with a minimum of self-reported current smoking pattern of >10 cigarettes/day during the last 6 months prior to screening, smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL)
- Patients that have been advised to quit smoking and informed of a smoking risk and cessation programs (per local SOC) and who are still not willing to set a quit date within the next 30 days at screening
- Stable treatment for coronary atherosclerosis according to the guidelines
- Have understood the study and have signed informed consent
Kryteria wyłączenia kto nie może wziąć udziału (19)
- Any acute cardiovascular event (i.e. ACS, MI, Stroke, TIA, Limb ischemia), unstable angina or revascularization within 30 days prior to screening
- Planned coronary intervention (PCI, CABG) at screening
- Previous CABG
- Preexisting heart failure with reduced ejection fraction (EF <50%)
- Severe uncontrolled hypertension (at the discretion of investigator)
- Diabetes
- Subjects with documented genetic familial hypercholesterolemia
- Subjects have known serious infection or chronic inflammatory systemic disease (e.g. rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis)
- Subjects have a known non-cardiovascular disease that is associated with poor prognosis (e.g. metastatic cancer)
- Patient with currently active cancer or history of cancer within the last 5 years
- Subjects have hypersensitivity or any other warnings listed in the local labeling for THS
- Subjects have hypersensitivity to imaging iodine contrast agents
- GFR<45 ml/min/1,73 m2
- Subjects who could not participate for any reason other than medical (e.g., psychological and/or social reason) per Investigator's judgment
- Subjects have any other clinical condition that would jeopardize the subject's safety while participating in this study, per Investigator's judgment
- Female subject is pregnant or breast-feeding, or planning to become pregnant during the study
- Subjects have previously participated in this study, or in an interventional study (drug or medical device) within 30 days of screening (participation in observational studies/registries allowed)
- Subjects have a close affiliation with the investigational site: a close relative of the investigator, a person dependent on the investigational site (e.g. employee or student of the investigational site)
- Subjects are current or former employee of the tobacco industry or their first-degree relatives (parent, child, spouse)
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Inne badania: zawał serca
RekrutujeFaza IV
Badanie kliniczne fazy IV
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Rekrutuje
Guzy neuroendokrynne: badanie kliniczne
COronoary Microcirculation Analysis NETwork
Rekrutuje
Badanie kliniczne
ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions
RekrutujeObserwacyjne
Badanie obserwacyjne
Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions
Rekrutuje
Badanie kliniczne
Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.